(97 days)
No
The device description and performance studies focus on mechanical properties, material science, and traditional medical device testing. There is no mention of AI, ML, image processing, or data-driven algorithms.
No
Explanation: The device is a system for facilitating percutaneous introduction of intravascular devices in radial arterial procedures, not for treating any specific condition. It acts as an access tool rather than providing therapy.
No
The device is described as an access system that facilitates direct radial access for intravascular devices, not as a tool for diagnosis. Its components are dilators, needles, and guidewires, which are used for percutaneous introduction, not for gathering diagnostic information.
No
The device description clearly outlines physical components such as dilators, needles, and guidewires, and the performance studies include bench testing on these physical attributes.
Based on the provided information, the RAILWAY™ Sheathless Access System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is for "radial arterial procedures requiring percutaneous introduction of intravascular devices." This describes a procedure performed directly on a patient's body, not on a sample of biological material outside the body.
- Device Description: The device components (dilators, needles, guidewires) are designed for accessing blood vessels and facilitating the insertion of other devices into the body.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body (like blood, urine, tissue, etc.) to provide information for diagnosis, monitoring, or screening.
Therefore, the RAILWAY™ Sheathless Access System is a medical device used for interventional procedures, not an IVD.
N/A
Intended Use / Indications for Use
The RAILWAY™ Sheathless Access System is indicated for use in radial arterial procedures requiring percutaneous introduction of intravascular devices.
Product codes (comma separated list FDA assigned to the subject device)
DYB
Device Description
The RAILWAY™ Sheathless Access System (hereafter referred to as "RAILWAY System" or "RAILWAY") facilitates the direct radial access of separately sold Cordis quiding catheters. Each RAILWAY System consists of two 136 cm nylon vessel dilators (0.021" and 0.035" quidewire compatible), a 20 Gauge IV cannula needle and/or a 21 Gauge stainless steel access needle, and a 45 cm 0.021" mini-guidewire (either stainless steel or hydrophilic coated Nitinol). The system configurations containing the hydrophilic guidewire do not contain a bare needle. The RAILWAY System has been dimensionally optimized for use with Cordis quiding catheters. The compatible guiding catheters and 0.035" guidewire are not included in the system.
The RAILWAY dilators have a tapered tip and a lubricious hydrophilic coating on the distal 20 cm section to facilitate access and ease of insertion. The geometry of the RAILWAY dilator taper and outer diameter (OD) have been optimized to provide atraumatic transitions between the dilator and a quiding catheter and between the dilator and quidewire. The dilator compatible with a 0.021" quidewire is intended for use in combination with a compatible guiding catheter to initiate sheathless (i.e. without a catheter sheath introducer) radial vascular access via insertion over a guidewire into the skin, subcutaneous tissue, and artery. After access is achieved, using either RAILWAY or a traditional catheter sheath introducer, the 0.035" RAILWAY dilator can be used to support the tracking of a compatible guiding catheter over a guidewire up to but not beyond the subclavian artery.
RAILWAY is available in ten (10) product configurations which differ on the basis of guiding catheter compatibility (catheter brand and French size) and the specific wire and needle(s) included in the system, as indicated in the table below. The dilators are color coded by size to align with accepted conventions for the guiding catheters to which the dilators are compatible. The RAILWAY System is a single-use sterile device, sterilized by ethylene oxide.
The RAILWAY System is compatible with 5F, 6F and 7F guiding catheters of 90 cm and 100 cm lengths. The dilators have been optimized for fit with either the Cordis VISTA BRITE TIP® or Cordis ADROIT® guiding catheters and have not been dimensionally optimized for compatibility with other guiding catheters. The appropriate RAILWAY dilator must be chosen to match the guidewire and guiding catheter sizes selected for the procedure. The RAILWAY System is for professional use in a hospital, catheterization laboratory, or other suitable healthcare facility only.
The materials of construction of the RAILWAY System components are as follows:
Dilator: Nylon, barium sulfate, color concentrate in polymer base, black ink, hydrophilic coating
Bare Wire: Stainless steel
Hydrophilic Wire: Nitinol, tungsten, hydrophilic coating
Bare Needle/Sheath: Stainless steel, resin, polyethylene
IV Cannula Needle: Stainless steel, MABS, polypropylene, FEP
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
radial artery
Indicated Patient Age Range
Not Found
Intended User / Care Setting
professional use in a hospital, catheterization laboratory, or other suitable healthcare facility only.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The performance data described below were provided in support of the substantial equivalence determination.
Biocompatibility Testing: The RAILWAY System, like the predicate, is an externally communicating device with limited contact duration (≤ 24 hours) with circulating blood. Biocompatibility testing was performed for RAILWAY in accordance with FDA Guidance Use of International Standard ISO 10993-1, Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process (June 16, 2016) and ISO 10993-1:2009/Cor 1:2010, Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process. On the basis of the testing listed below, RAILWAY is biocompatible for its intended use:
- Cytotoxicity
- Sensitization
- Irritation
- Systemic toxicity
- Pyrogenicity
- Genotoxicity
- Hemocompatibility
Sterilization: The sterilization cycle used to sterilize RAILWAY™ was validated per ISO 11135:2014 Sterilization of health-care products - Ethylene oxide - Requirements for the development, validation and routine control of a sterilization process for medical devices to provide a sterility assurance level (SAL) of 10-6. Ethylene oxide and ethylene chlorohydrin residuals meet requirements for limited exposure devices (contact
§ 870.1340 Catheter introducer.
(a)
Identification. A catheter introducer is a sheath used to facilitate placing a catheter through the skin into a vein or artery.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, and then the word "ADMINISTRATION" in a smaller font size below.
April 18, 2018
Cordis Corporation Ms. Ankita Phophalia Project Manager, Regulatory Affairs 1820 McCarthy Boulevard Milpitas, California 95035
Re: K180081
Trade/Device Name: RAILWAY Sheathless Access System Regulation Number: 21 CFR 870.1340 Regulation Name: Catheter Introducer Regulatory Class: Class II Product Code: DYB Dated: March 16, 2018 Received: March 19, 2018
Dear Ms. Phophalia:
We have reviewed vour Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
Page 2 - Ankita Phophalia
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone
(1-800-638-2041 or 301-796-7100).
Sincerely,
M.A. Hillemann
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K180081
Device Name RAILWAY Sheathless Access System
Indications for Use (Describe)
The RAILWAY Sheathless Access System is indicated for use in radial arterial procedures requiring percutaneous introduction of intravascular devices.
Type of Use (Select one or both, as applicable)|X Prescription Use (Part 21 CFR 801 Subpart D)
| | Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary - K180081
I. SUBMITTER
Applicant: Cordis Corporation 14201 North West 60th Avenue Miami Lakes, Florida 33014 USA Establishment Reqistration: 1016427
Contact: Ankita Phophalia Cordis Corporation 1820 McCarthv Boulevard Milpitas, CA 95035 USA Tel: (408) 273-3228 (408) 955-0704 Fax:
Date Prepared: January 10, 2018
II. DEVICE
Name of Device: RAILWAY™ Sheathless Access System Common Name: Vascular Catheter Introducer Classification Name: Introducer, Catheter (21 CFR 870.1340), Class II Product Code: DYB
III. PREDICATE DEVICE
Terumo Glidesheath Slender® cleared on 11/21/2014 under K142183
Reference device Terumo Glidesheath Slender® cleared on 12/11/2012 under K122980 Asahi Sheathless Eaucath Coronary Guide Catheter cleared on 10/24/2013 under K132556
None of the predicate or reference devices cited above have been the subject of a recall.
IV. DEVICE DESCRIPTION
The RAILWAY™ Sheathless Access System is indicated for use in radial arterial procedures requiring percutaneous introduction of intravascular devices.
The RAILWAY™ Sheathless Access System (hereafter referred to as "RAILWAY System" or "RAILWAY") facilitates the direct radial access of separately sold Cordis quiding catheters. Each RAILWAY System consists of two 136 cm nylon vessel dilators (0.021" and 0.035" quidewire compatible), a 20 Gauge IV cannula needle and/or a 21 Gauge stainless steel access needle, and a 45 cm 0.021" mini-guidewire (either stainless steel or hydrophilic coated Nitinol). The system configurations containing the hydrophilic guidewire do not contain a bare needle. The RAILWAY
4
System has been dimensionally optimized for use with Cordis quiding catheters. The compatible guiding catheters and 0.035" guidewire are not included in the system.
The RAILWAY dilators have a tapered tip and a lubricious hydrophilic coating on the distal 20 cm section to facilitate access and ease of insertion. The geometry of the RAILWAY dilator taper and outer diameter (OD) have been optimized to provide atraumatic transitions between the dilator and a quiding catheter and between the dilator and quidewire. The dilator compatible with a 0.021" quidewire is intended for use in combination with a compatible guiding catheter to initiate sheathless (i.e. without a catheter sheath introducer) radial vascular access via insertion over a guidewire into the skin, subcutaneous tissue, and artery. After access is achieved, using either RAILWAY or a traditional catheter sheath introducer, the 0.035" RAILWAY dilator can be used to support the tracking of a compatible guiding catheter over a guidewire up to but not beyond the subclavian artery.
RAILWAY is available in ten (10) product configurations which differ on the basis of guiding catheter compatibility (catheter brand and French size) and the specific wire and needle(s) included in the system, as indicated in the table below. The dilators are color coded by size to align with accepted conventions for the guiding catheters to which the dilators are compatible. The RAILWAY System is a single-use sterile device, sterilized by ethylene oxide.
The RAILWAY System is compatible with 5F, 6F and 7F guiding catheters of 90 cm and 100 cm lengths. The dilators have been optimized for fit with either the Cordis VISTA BRITE TIP® or Cordis ADROIT® guiding catheters and have not been dimensionally optimized for compatibility with other guiding catheters. The appropriate RAILWAY dilator must be chosen to match the guidewire and guiding catheter sizes selected for the procedure. The RAILWAY System is for professional use in a hospital, catheterization laboratory, or other suitable healthcare facility only.
| RAILWAY™ Sheathless Access System Product Configurations | ||||||
|---|---|---|---|---|---|---|
| Catalog | ||||||
| Code | Access | |||||
| Mini-GuideWire | Access | |||||
| Needle | Vessel | |||||
| Dilator | ||||||
| Color | Recommended | |||||
| Guiding Catheter | ||||||
| Compatibility | ||||||
| (Inner Diameter) | Dilator | |||||
| Guidewire | ||||||
| Compatibility | Dilator | |||||
| Max | ||||||
| Outer | ||||||
| Diameter | ||||||
| RW5ADTH | Hydrophilic | IV | Gray | 5F Cordis ADROIT® | ||
| (0.058") | 0.021" and | |||||
| 0.035" | 0.057" / | |||||
| 1.45 mm | ||||||
| RW5ADTB | Bare | Bare/IV | 5F Cordis ADROIT® | |||
| (0.058") | 0.021" and | |||||
| 0.035" | 0.057" / | |||||
| 1.45 mm | ||||||
| RW5VBTH | Hydrophilic | IV | 5F Cordis VISTA | |||
| BRITE TIP® (0.056") | 0.021" and | |||||
| 0.035" | 0.056" / | |||||
| 1.41 mm | ||||||
| RW5VBTB | Bare | Bare/IV | 5F Cordis VISTA | |||
| BRITE TIP® (0.056") | 0.021" and | |||||
| 0.035" | 0.056" / | |||||
| 1.41 mm | ||||||
| RW6ADTH | Hydrophilic | IV | Green | 6F Cordis ADROIT® | ||
| (0.072") | 0.021" and | |||||
| 0.035" | 0.071" / | |||||
| 1.80 mm | ||||||
| RW6ADTB | Bare | Bare/IV | 6F Cordis ADROIT® | |||
| (0.072") | 0.021" and | |||||
| 0.035" | 0.071" / | |||||
| 1.80 mm | ||||||
| RW6VBTH | Hydrophilic | IV | 6F Cordis VISTA | |||
| BRITE TIP® (0.070") | 0.021" and | |||||
| 0.035" | 0.070" / | |||||
| 1.77 mm | ||||||
| RW6VBTB | Bare | Bare/IV | 6F Cordis VISTA | |||
| BRITE TIP® (0.070") | 0.021" and | |||||
| 0.035" | 0.070" / | |||||
| 1.77 mm | ||||||
| RW7VBTH | Hydrophilic | IV | Orange | 7F Cordis VISTA | ||
| BRITE TIP® | ||||||
| (0.078") | 0.021" and | |||||
| 0.035" | 0.078" / | |||||
| 1.97 mm | ||||||
| RW7VBTB | Bare | Bare/IV | 7F Cordis VISTA | |||
| BRITE TIP® | ||||||
| (0.078") | 0.021" and | |||||
| 0.035" | 0.078" / | |||||
| 1.97 mm |
5
| RAILWAY™ Sheathless Access System
| Materials of Construction | ||
|---|---|---|
| Component | Materials | Patient |
| Contact | ||
| Dilator | Nylon, barium sulfate, color concentrate in | |
| polymer base, black ink, hydrophilic coating | Direct | |
| (≤ 24hr) | ||
| Bare Wire | Stainless steel | Direct |
| (≤ 24hr) | ||
| Hydrophilic | ||
| Wire | Nitinol, tungsten, hydrophilic coating | Direct |
| (≤ 24hr) | ||
| Bare Needle/ | ||
| Sheath | Stainless steel, resin, polyethylene | Direct |
| (≤ 24hr) | ||
| IV Cannula | ||
| Needle | Stainless steel, MABS, polypropylene, FEP | Direct |
| (≤ 24hr) |
The materials of construction of the RAILWAY System components are as follows:
V. INDICATIONS FOR USE
The RAILWAY™ Sheathless Access System is indicated for use in radial arterial procedures requiring percutaneous introduction of intravascular devices.
The Indications for Use statement for RAILWAY is not identical to that of the predicate device. However, the subject and predicate devices have the same fundamental intended use, which is to facilitate placement of intravascular catheters into the radial artery. Differences in the Indications for Use statements do not alter the intended use nor do they affect the substantial equivalence of the device relative to the predicate.
VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE
The RAILWAY™ Sheathless Access System and the predicate device facilitate low profile access into the radial artery using the same fundamental mechanism of action. After gaining access with a needle and wire, the thermoplastic dilator component of each system supports the device in which it is inserted, dilates the radial artery, and provides smooth transitions between the guidewire and the device being introduced. Both devices use a tapered, dimensionally-optimized dilator supporting an outer device and a lubricious hydrophilic coating to facilitate atraumatic entry into the radial artery.
The RAILWAY System has the following similarities to the predicate device:
- . Same intended use
- . Same principle of operation
- Same mechanism of action ●
- . Same method of sterilization and sterility assurance level
- Same biocompatibility classification ●
- Biocompatible for intended use
- Labeled non-pyrogenic ●
6
- Similar materials ●
- Similar components ●
- Similar device dimensions ●
- . Similar packaging configuration
- Similar compatibility with other devices used in radial access procedures ●
The following technological differences exist between the subject and predicate devices:
- RAILWAY System does not include a sheath
- RAILWAY dilators do not include a hub ●
- RAILWAY dilators possess a wire port and printed markers .
- RAILWAY dilator is longer; working length is similar ●
- Hydrophilic coating is applied to RAILWAY dilator, whereas the predicate has ● a hydrophilic coating on the sheath
- . RAILWAY dilators can support guiding catheter tracking up to but not beyond the subclavian artery
Based on a thorough analysis of technological characteristics, including design, materials, dimensions, mechanism of action, and clinical use, the differences between the RAILWAY System and the predicate do not raise different questions of safety and effectiveness for use during radial access. No different questions of safety and effectiveness are raised by the RAILWAY System for supported tracking of a guiding catheter over a guidewire relative to use of a guiding catheter introduced through a sheath and tracked over a guidewire up to but not beyond the subclavian artery.
VII. PERFORMANCE DATA
The performance data described below were provided in support of the substantial equivalence determination.
Biocompatibility Testing
The RAILWAY System, like the predicate, is an externally communicating device with limited contact duration (≤ 24 hours) with circulating blood. Biocompatibility testing was performed for RAILWAY in accordance with FDA Guidance Use of International Standard ISO 10993-1, Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process (June 16, 2016) and ISO 10993-1:2009/Cor 1:2010, Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process. On the basis of the testing listed below, RAILWAY is biocompatible for its intended use:
- Cytotoxicity .
- Sensitization
- Irritation ●
- Systemic toxicity ●
- Pyrogenicity ●
- Genotoxicity ●
- . Hemocompatibility
7
Sterilization
The sterilization cycle used to sterilize RAILWAY™ was validated per ISO 11135:2014 Sterilization of health-care products - Ethylene oxide - Requirements for the development, validation and routine control of a sterilization process for medical devices to provide a sterility assurance level (SAL) of 10-6.
Ethylene oxide and ethylene chlorohydrin residuals meet requirements for limited exposure devices (contact